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Summary Background Lapatinib has proven efficacy as
monotherapy and in combination with capecitabine in patients
with metastatic breast cancer (MBC) overexpressing HER2
and/or EGFR. Gemcitabine also has anti-tumor activity in
MBC and a favourable toxicity profile. In this phase I study
lapatinib and gemcitabine were combined. Methods Female
patients with advanced BC were given lapatinib once daily
(QD) in 28-day cycles with gemcitabine administered on
day 1, 8 and 15. Physical examinations, vital signs and blood
sampling for hematology, clinical chemistry and pharmacoki-
netics (PK) and radiological assessments of disease were per-
formed at regular intervals. Results In total, 33 patients were
included. Six dose-limiting toxicities were observed, mostly
grade 3 increases in liver function tests. Most common toxic-
ities were fatigue (73 %), nausea (70 %), diarrhea (58 %),
increases in ALAT and ASAT (55 and 52 %, respectively)
and rash (46 %). The maximum tolerated dose was lapatinib
1250 mg QD with gemcitabine 1000 mg/m2. Lapatinib and
gemcitabine PK did not appear to be influenced by each other.
Anti-tumor activity was observed with one patient (4 %)
showing complete response and six (23 %) partial response.
Conclusion Despite a slightly increased toxicity profile com-
pared to their respective monotherapies, lapatinib and
gemcitabine can be safely combined while showing signs of
anti-tumor activity.
Keywords Lapatinib . Gemcitabine . Advanced breast
cancer . Phase I trial
Introduction
Globally, breast cancer is the most frequently diagnosed can-
cer and the leading cause of cancer death in both economically
developed and developing countries. It accounts for 23 % of
new cancer cases and 14 % of cancer deaths worldwide (data
from 2008) [1].
In the 1980s, it was discovered that overexpression of hu-
man epidermal growth factor receptor 2 (HER2/neu) is asso-
ciated with poor patient prognosis and survival [2]. HER2 and
its rodent analogue neu are oncogenic receptors that, when
activated, can trigger multiple intracellular signalling path-
ways, such as the mitogen-activated protein kinase (MAPK)-
and phosphoinositide 3-kinase (PI3K)-pathway, leading to
cell survival and proliferation [3, 4]. Therefore, this receptor
rapidly became an attractive target for inhibition, leading to
the development of trastuzumab (Herceptin®) [5]. This hu-
manized, monoclonal antibody against HER2/neu has since
then become an effective treatment option for women with
metastatic, HER2-overexpressing breast cancers, both as
monotherapy and in combination with chemotherapy [6]. It
has also shown to improve survival in the adjuvant setting in
patients with HER2-overexpressing breast cancer [7].
Unfortunately, the majority of the patients treated
with trastuzumab tend to develop resistance to this drug
within 1 year after starting treatment. Anti-tumor
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activity may be regained by switching the combination
of trastuzumab and chemotherapy into trastuzumab plus
another cytotoxic agent. However, development of new
therapeutic strategies is needed to overcome trastuzumab
resistance [8]. Lapatinib is a dual tyrosine kinase inhib-
itor, targeted against both the epidermal growth factor
receptor (EGFR) and HER2/neu [9]. It has shown mod-
erate clinical anti-tumor activity as monotherapy in pa-
tients overexpressing HER2/neu and/or EGFR and has a
relatively mild toxicity profile with main adverse events
consisting of diarrhea and rash [10–12]. Importantly, it
has shown anti-tumor activity in patients that had pre-
viously progressed on trastuzumab [13]. Adding
lapatinib to a chemotherapy regimen has proven to in-
crease its anti-tumor activity, as evidenced by the FDA
and EMA approval of lapatinib in combination with
capecitabine for previously treated, metastatic, HER2-
overexpressing breast cancer [14, 15].
Toxicities observed with this combination in the phase III
and registration study only showed increased diarrhea and
rash when compared to capecitabine alone, as was expected
[16]. These encouraging results warrant further research into
combining lapatinib with other cytotoxic agents.
Gemcitabine is a prodrug, which is intracellularly me-
tabolized to its active forms difluorodeoxycytidine diphos-
phate and triphosphate (dFdCDP and dFdCTP). dFdCDP
reduces the number of natural deoxynucleotides, including
deoxycytidine triphosphate (dCTP). Additionally, dFdCTP
competes with dCTP for incorporation into the DNA and
subsequently inhibits DNA synthesis, resulting in cell
death [17]. The first approval for gemcitabine was as a
treatment modality for pancreatic cancer [18–20]. Due to
its favourable toxicity profile, gemcitabine can be com-
bined with other anti-cancer treatments, which for instance
led to its use in patients with non-small cell lung cancer
(NSCLC) and bladder cancer in combination with cisplatin
[21, 22].
Since gemcitabine has shown activity in patients with met-
astatic breast cancer [23, 24], this study intended to investigate
whether a combination of lapatinib and gemcitabine could be
a feasible treatment option for women with advanced breast
cancer. In order to explore the anti-tumor activity of this com-
bination the optimal dose and schedule had to be determined.
Patients and methods
All patients provided written informed consent. The study was
conducted in accordance with the Declaration of Helsinki,
Good Clinical Practice and applicable regulatory require-
ments. The study was approved by the local ethical review
board.
Patient selection and eligibility
This study was performed at the Netherlands Cancer Institute
(NKI) in Amsterdam, the Netherlands and Medisch Spectrum
Twente (MST) in Enschede, the Netherlands. It was conduct-
ed in women with advanced breast cancer who had previously
been treated with an anthracycline and a taxane (either in
adjuvant or palliative setting) and were then considered to be
candidates for palliative chemotherapy with gemcitabine. El-
igibility criteria included: age≥18 years; ECOG performance
status≤2; measurable diseases according to Response Evalu-
ation Criteria in Solid Tumors (RECIST); adequate bone mar-
row, hepatic and renal function (as evidenced by thrombo-
cytes≥100*109/L; absolute neutrophile count≥1.5*109/L; he-
moglobin≥6.2 mmol/L; total bilirubin≤1.5× upper normal
limit (ULN); serum aspartate aminotransferase (ASAT) and
alanine aminotransferase (ALAT)≤2.5× ULN and creati-
nine≤1.5× ULN); previously treated with trastuzumab (in
case of HER2-overexpression); no other investigational drugs
within 30 days prior to start. Furthermore, no concomitant
medication classified as a CYP3A4 inducer or inhibitor was
allowed, since lapatinib is a CYP3A4 substrate. Patients with
a clinically significant cardiac impairment (left ventricular
ejection fraction (LVEF) of≤50 %) or unstable ischemic heart
disease including a myocardial infarction (<3 months of study
entry) were not included in this study.
Study design and procedures
The primary objectives of this phase I study were to determine
the safety and tolerability, maximum tolerated dose (MTD),
dose-limiting toxicities (DLTs) and optimal treatment sched-
ule of lapatinib combined with gemcitabine. Secondary objec-
tives were to explore the pharmacokinetic (PK) profile and
anti-tumor activity of the combination.
Dose escalation in this study followed a classical 3+3 de-
sign. DLTs were defined as any of the following events deter-
mined to be possibly, probably or definitely related to treat-
ment during the first cycle: grade≥3 non-hematological tox-
icities; grade≥3 nausea, vomiting or diarrhea in the presence
of maximal support; grade 4 thrombocytopenia; grade 4 neu-
tropenia for>7 consecutive days; or grade 3 febrile
neutropenia.
The cohort below the non-tolerated dose (i.e., the cohort in
which 2 or more out of 6 patients experiences a DLT) was
expanded with 6 patients to confirm this dose-level as the
MTD.
Drug administration and dosing schedule
One treatment cycle was defined as 28 days. Lapatinib was
administered orally daily in escalating doses, starting from
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750mg once daily (QD). Gemcitabine was given as a standard
30-min intravenous infusion on day 1, 8 and 15 of every cycle.
Safety evaluations
Physical examinations and the assessments of vital signs, per-
formance status and routine clinical chemistry and hematolo-
gy were performed at baseline and on day 1, 8 and 15 of the
first 2 treatment cycles and on day 1 and 8 of subsequent
cycles. A 12-lead ECG was performed at baseline and at the
start of every treatment cycle, starting at cycle 2. A chest X-
ray and MUGA-scan for measurement of the LVEF was made
at baseline and after every 2 treatment cycles.
Adverse events were recorded at every visit and graded
according to the National Cancer Institute Common Terminol-
ogy Criteria of Adverse Events (NCI-CTCAE) version 3.0
[25].
Pharmacokinetic and pharmacodynamic analysis
Plasma samples for the bioanalysis of lapatinib were col-
lected at predose and 30 min, 1, 2, 4, 8 and 24 h after
oral administration. Additional plasma samples were tak-
en predose on day 8, 15 and 29 (cycle 2 day 1). Plasma
concentrations of lapatinib were measured using a vali-
dated liquid chromatography/tandem mass spectrometry
method [26].
Blood samples for gemcitabine were collected prior to,
at the end of infusion and 1, 2, 4, 8 and 24 h after
s t a r t o f i n fu s i on . P l a sma gemc i t ab in e (2 ′ , 2 ′ -
difluorodeoxycytidine, dFdC) and its metabolite 2′,2′-
difluorodeoxyuridine, dFdU) concentrations were ana-
lyzed as described before [27], with the exception that
tetrahydrouridine was not added to the sodium-heparine
blood collection tubes. Additionally, intracellular concen-
trations of the active metabolite of gemcitabine,
difluorodeoxycytidine triphosphate (dFdCTP), were mea-
sured as described previously in peripheral blood mono-
nuclear cells (PBMCs) [28] prior to, at the end of infusion
and 2 and 24 h after start of infusion.
Assessment of anti-tumor activity
Tumor measurements were performed by CT or MRI-scan at
baseline and after every 2 treatment cycles. Scans were then
evaluated according to Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.0 [29].
Furthermore, the tumor markers cancer antigen 15.3
(CA15.3) and carcinoembryonic antigen (CEA) were mea-
sured at baseline and after every 2 treatment cycles.
Results
Patient characteristics
In total, 33 female patients with advanced breast cancer were
included in this study, between November 2007 and Novem-
ber 2012. Table 1 shows the patient characteristics.
Four patients had to be replaced per protocol because they
received<80 % of study medication during the first cycle to
ensure that at least 3 subjects were evaluable for safety over
the whole course of the first cycle. The median age of patients
in this study was 50 years (36–73). They were heavily pre-
treated with approximately half of all patients (54 %) having
received≥4 lines of chemotherapy. Additionally, 70 % of the
patients received prior hormonal therapy, 64%were previous-
ly treated with trastuzumab and 88 % had received prior ra-
diotherapy. HER2-overexpression was demonstrated in the
tumors of 22 patients (67 %).
Dose-Limiting Toxicities (DLTs) and Maximum Tolerated
Dose (MTD)
Five escalating dose-levels were explored in this study (see
table 2). In total, six DLTs were observed across four dose-
levels. In five cases, the DLT concerned a grade 3 increase in
Table 1 Patient characteristics
Characteristic
No. of patients 33
Age, years Median (range) 50 (36–73)
Ethnic origin, n (%) Caucasian 30 (91)
East/Southeast Asian 2 (6)
Hispanic 1 (3)
ECOG performance status, n (%) 0 11 (33)
1 18 (55)
2 4 (12)




Prior hormonal therapy, n (%) 23 (70)
Prior immunotherapy, n (%) 21 (64)
Prior radiotherapy, n (%) 29 (88)
HER2-overexpression, n (%) Yes 22 (67)
No 10 (30)
Unknown 1 (3)
LVEF, % Median (range) 56 (52–73)
CA15.3, kU/L Median (range) 110 (11–770)
Patient characteristics. LVEF left ventricular ejection fraction, CA cancer
antigen
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ASAT and/or ALAT. This increase generally occurred 1 to
2 weeks after start of the first cycle, leading to an interruption
of lapatinib dosing and omission of gemcitabine infusions.
Two patients showed progression of disease after this DLT
and did not re-start treatment; in the other three patients the
liver function tests recovered and cycle 2 was administered,
albeit with a dose reduction of gemcitabine with 25 % and
lapatinib with 250 mg. Additionally, one DLT of grade 3 di-
arrhea was observed at the highest dose-level explored, de-
spite maximal support with loperamide and ciprofloxacin.
Lapatinib was interrupted and gemcitabine omitted. This pa-
tient was not re-started on treatment.
At the time the study was ongoing, only one DLT (grade 3
elevation in both ASAT and ALAT) was recorded in dose-
level 3, which was then expanded. Since no other DLTs were
seen in the dose expansion, the dose was escalated to dose-
level 4. A second DLT (grade 3 elevation in ALAT) in dose-
level 3 was not noted until study data were carefully re-
analysed.
Since dose-level 5 was not considered to be tolerable with
two out of six patients experiencing a DLT, the MTD was set
at dose-level 4, consisting of lapatinib 1250 mg QD (day 1–
28) and gemcitabine 1000mg/m2 (day 1, 8 and 15). This dose-
level was then expanded with six additional patients, none of
whom experienced DLTs.
Adverse events
Treatment-related adverse events (TRAEs) observed in≥10%
of patients in this study are presented in Table 3.
The most commonly observed possibly, probably or defi-
nitely TRAEs were fatigue (73 %), nausea (70 %), diarrhea
(58 %), increases in ALAT and ASAT (55 and 52 %, respec-
tively), rash (46 %) and neutropenia (39 %).
Adverse events that were grade 3 or higher mostly
consisted of neutropenia (39 %), elevated ALAT and ASAT
(18 and 15 %, respectively) and diarrhea (9 %).
Interrupting lapatinib dosing and omitting gemcitabine in-
fusion improved the observed toxicities and led to recovery of
hematological and biochemical laboratory values. Nausea and
diarrhea were mostly mild (grade 1–2), but in some cases
these toxicities required concomitant treatment. Nausea was
initially treated with metoclopramide, however, in more se-
vere cases granisetron was required. Diarrhea sometimes re-
quired treatment with loperamide. Rash was mild (grade 2 or
lower) in all cases and responded to local treatment, such as
with metronidazole crème or systemic anti-histaminic treat-
ment, such as with levocetirizine.
While there were five patients who demonstrated a median
decrease in LVEF of 10 % (range 8–14 %) after two cycles,
the patients who remained on study for six cycles or longer
showed stable LVEF values.
Pharmacokinetics
PK parameters and plasma concentration-time curves of
lapatinib and gemcitabine (dFdC and dFdU) and intracellular
concentrations of dFdCTP are presented in table 4 and Fig. 1.
Lapatinib
Plasma samples for the PK of lapatinib were collected and
analyzed in 28 patients. The PK of lapatinib showed high
interpatient variability (see Fig. 1a). The median time to max-
imum concentration (Tmax) was mostly observed at 4.0 h
(range 2.0–8.1). The maximum plasma concentration (Cmax)
increased with dose and this increase appeared to be dose-
proportional. Since the blood sampling did not cover>80 %
of the area under the plasma concentration-time curve (AUC)
due to a long elimination phase, the AUC0-∞ and terminal half-
life (t1/2) could not be determined from the obtained data.
Gemcitabine
The PK parameters for dFdC and dFdU were determined in
plasma collected from 30 patients. See Fig. 1b and c.
The dose-normalized Cmax and AUC0–24 did not differ sig-
nificantly amongst dose-levels, although there was high vari-
ation in the first three patients on study.
For the metabolite dFdU, the Cmax followed closely after
dFdC, indicating rapid formation of this metabolite. Both
Cmax and AUC0-∞ increased dose-proportionally across the
different dose-levels.
Pharmacodynamics
PBMCs of 26 patients were available for the analysis of intra-
cellular dFdCTP concentration. However, in about half of the
patients the dFdCTP measurements were below the lower
limit of quantification (LLOQ) and were therefore not used
in further analyses. The results obtained in 13 patients are
shown in Fig. 1d. High variability was observed; therefore











The dose-levels explored in this study
1200 Invest New Drugs (2015) 33:1197–1205
Anti-tumor activity
Out of the 33 patients included in this study, 26 had at least
one response evaluation (see table 5); seven patients had gone
off study without receiving one full cycle because of rapid
clinical disease progression. One patient (4 %) demonstrated
radiological complete response (CR) and another six patients
(23%) achieved a partial response (PR), resulting in an overall
response rate (ORR: CR+PR) of 27 %. Five of the patients
that had radiological PR also demonstrated clear reductions in
their tumor markers (both CA15.3 and CEA). An additional
12 patients (46 %) had stable disease (SD) as best response.
Radiological responses were mostly observed at higher dose-
levels (≥ level 3). Furthermore, the patient with CR and 5/6
patients with PR demonstrated tumors that overexpressed
HER2.
Median duration on study for the evaluable population was
13 weeks, ranging from 2 to 49 weeks.
Discussion
In this phase I study, the combination of lapatinib with
gemcitabine did not result in unexpected toxicities. The
MTD of the combination was defined at lapatinib 1250 mg
QD (day 1–28) with gemcitabine 1000 mg/m2 (day 1, 8 and
15). The most frequently observed TRAEs were in line with
toxicities that are observed with gemcitabine and lapatinib
monotherapy. Both frequency and severity of TRAEs in-
creased with escalating dose-levels. The DLTs that were ob-
served in this study did not correspond to higher exposures to
study drug, except for the patient who experienced grade 3
diarrhea despite maximal support with loperamide and cipro-
floxacin. This patient showed the highest exposure to lapatinib
out of all patients on study, which could explain the persisting
toxicity. The most common adverse events seen with
lapatinib, diarrhea and rash (42 and 31 %, respectively, in
the lapatinib monotherapy phase I study) [10], were also ob-
served in this study albeit with slightly increased frequency
(58 and 46 %, respectively). In all cases, rash was mild (grade
1–2) and appeared to respond to local or systemic treatment.
The diarrhea was also mostly mild and manageable with con-
comitant treatment of loperamide.
Hematological and biochemical toxicities, such as neutro-
penia and elevated ALAT and ASAT, were also increased in
the lapatinib/gemcitabine combination (39, 55 and 52 %, re-
spectively) when compared to gemcitabine monotherapy (26,
39 and 31 %, respectively) [18].
Table 3 Treatment-related
adverse events Adverse event Dose-level Total
1 2 3 7 5
No. of patients 3 4 8 10 8 33
Fatigue All grades 2 (67) 3 (75) 7 (88) 7 (70) 5 (63) 24 (73)
Grade ≥3 0 0 1 (13) 0 0 1 (3)
Nausea All grades 1 (33) 4 (100) 7 (88) 4 (40) 7 (88) 23 (70)
Grade ≥3 0 0 1 (13) 0 0 1 (3)
Diarrhea All grades 2 (67) 2 (50) 4 (50) 5 (50) 6 (75) 19 (58)
Grade ≥3 0 0 1 (13) 1 (10) 1 (13) 3 (9)
Elevated ALAT All grades 1 (33) 3 (75) 5 (63) 5 (50) 4 (50) 18 (55)
Grade ≥3 0 1 (25) 2 (25) 1 (10) 2 (25) 6 (18)
Elevated ASAT All grades 1 (33) 3 (75) 5 (63) 4 (40) 4 (50) 17 (52)
Grade ≥3 0 1 (25) 3 (38) 1 (13) 5 (15)
Rash* All grades 0 2 (50) 4 (50) 5 (50) 4 (50) 15 (46)
Grade ≥3 0 0 0 0 0 0
Neutropenia All grades 2 (67) 2 (50) 1 (13) 5 (50) 3 (38) 13 (39)
Grade ≥3 2 (67) 2 (50) 1 (13) 5 (50) 3 (38) 13 (39)
Vomiting All grades 0 2 (50) 5 (63) 2 (20) 2 (25) 11 (33)
Grade ≥3 0 0 1 (13) 0 0 1 (3)
Fever All grades 1 (33) 1 (25) 2 (25) 2 (20) 2 (25) 8 (24)
Grade ≥3 0 0 0 0 0 0
Mucositis# All grades 0 1 (25) 1 (13) 2 (20) 3 (38) 7 (21)
Grade ≥3 0 0 0 0 0 0
Treatment-related adverse events per dose-level. *includes desquamation, acneiform, erythema. # both clinical
examination and symptomatic
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Overall, these data suggest that combining these com-
pounds does result in slightly increased toxicity when com-
pared to either of these agents alone. This resulted in a lower
lapatinib dose in the MTD of this study (1250 mg) than the
dose that is recommended as monotherapy (1500 mg).
Gemcitabine however could be administered at the recom-
mended monotherapy dose of 1000 mg/m2.
The PK of lapatinib showed high interpatient variability.
The dose-normalized Cmax did not differ significantly between
the different dose-levels. However, no sampling was done for
lapatinib alone thus no direct treatment comparisons could be
made. Furthermore, patient numbers were small, making it
difficult to draw definitive conclusions about the influence
of gemcitabine on lapatinib PK.
Less variation was seen in the PK of gemcitabine (dFdC)
and its metabolite dFdU. For both dFdC and dFdU, PK ap-
peared to be similar to gemcitabine monotherapy [30], sug-
gesting that co-administration of lapatinib did not influence
gemcitabine PK.
The measurement of dFdCTP was performed in about half
of the patients, since many of the samples were below the
LLOQ. We suspect that this might be due to the sample pro-
cessing. Most of the later samples were not washed with ice-
cold PBS as described in the validated method [28] or proc-
essed on ice, which could have led to an increase in the rate of
degradation of dFdCTP. In the subjects where dFdCTP could
be determined it showed very high variability, although Cmax
values found were similar to those in literature with similar
doses of gemcitabine [31].
Although not the primary objective of this study, the ORR
observed in this study (27 % for all evaluable patients; 21 %
for evaluable patients whose tumor overexpressed HER2) is in
line with the lapatinib/capecitabine (1250 mg continuously/
2000 mg/m2 on day 1–14) combination (ORR of 22 %) in
the phase III trial in a similar population.(16) However, this
conclusion has to be considered carefully since patient num-
bers were much smaller in this phase I study (26 patients
evaluable for response compared to 163 patients in the Geyer
study) and in this study HER2-expression was not an inclu-
sion criterium.
The combination of lapatinib with gemcitabine (and
oxaliplatin) has been investigated clinically before in patients
with pancreatic and biliary cancer. In a phase I study in this
population the MTD of lapatinib with gemcitabine was set at
1500 mg and 1000 mg/m2 respectively, with only 1 DLT of
grade 3 diarrhea [32]. A subsequent phase II study of
lapatinib/gemcitabine was performed in patients with metasta-
tic pancreatic cancer. Toxicities were mostly hematologic
(30 % experienced grade 3 or 4 neutro- or thrombocytopenia);
fatigue, diarrhea, elevated ASAT/ALATand anorexia were the
most frequent non-hematological grade≥2 adverse events.
Unfortunately, the combination failed to improve the overall
Table 4 Pharmacokinetic parameters
Dose-level 1 2 3 4 5
Lapatinib QD (mg) 750 750 1000 1250 1500
Gemcitabine (mg/m2) 750 1000 1000 1000 1000
Lapatinib (median (range))
n=3 n=4 n=7 n=9 n=7
Cmax (ng/mL) 807 (436–1614) 872 (540–1200) 818 (450–1294) 1258 (573–2231) 1314 (1030–3108)
Dose-normalized Cmax (ng/mL*mg) 1.1 (0.6–2.2) 1.2 (0.7–1.6) 0.8 (0.5–1.3) 1.0 (0.5–1.8) 0.9 (0.7–2.1)
Tmax (hr) 4.0 (4.0–4.1) 4.0 (2.1–4.4) 4.0 (2.0–8.1) 4.0 (2.1–8.0) 4.2 (4.0–6.9)
Gemcitabine (median (range))
dFdC n=3 n=4 n=7 n=9 n=7
Cmax (ug/mL) 9.5 (1.2–4.6) 9.1 (7.4–13.0) 10.9 (4.4–14.8) 9.2 (5.0–21.5) 10.2 (1.4–20.0)
Dose-normalized Cmax (ng/mL*mg) 7.6 (1.0–38.4) 5.4 (4.7–6.2) 6.2 (2.3–7.4) 4.8 (0.6–12.1) 5.7 (0.9–10.5)
AUC0-24 (ug*hr/mL) 7.1 (1.0–24.8) 6.4 (5.2–7.6) 7.9 (3.3–11.3) 7.8 (0.6–17.1) 6.8 (1.2–10.5)
dFdU n=3 n=4 n=7 n=9 n=7
Cmax (ug/mL) 20.8 (18.2–44.3) 46.4 (29.5–59.3) 33.5 (26.4–52.4) 36.4 (33.3–63.9) 37.6 (26.8–54.9)
Dose-normalized Cmax (ng/mL*mg) 16.6 (14.3–36.9) 24.1 (18.4–37.8) 19.9 (16.5–26.2) 21.4 (17.9–39.9) 21.4 (15.8–28.9)
AUC0-∞ (ug*hr/mL) 196 (185–202) 282 (232–505) 272 (188–496) 306 (226–461) 324 (272–359)
Terminal half-life (t1/2) (hr) 9.1 (8.1–11.5) 9.0 (7.5–9.9) 10.3 (6.3–11.0) 8.9 (8.0–9.7) 9.6 (8.1–13.4)
dFdCTP n=3 n=3 n=5 n=2 NA
Cmax (pmol/10*6 cells) 63 (51–69) 59 (54–62) 42 (33–84) 147 (128–165) NA
Tmax (hr) 2.0 (0.6–2.0) 0.8 (0.6–2.0) 1.9 (0.7–2.1) 2.0 (2.0–2.1) NA
Pharmacokinetic parameters of lapatinib and gemcitabine (dFdC, dFdU and dFdCTP) per dose-level
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survival rate in this patient population [33]. In a recent pre-
clinical study lapatinib was tested in combination with
gemcitabine to investigate whether these drugs showed syn-
ergistic or antagonistic effects in pancreatic cancer cell lines.
There was no clear effect observed and thus the authors con-
cluded that lapatinib may not enhance the anti-tumor effects of
gemcitabine in pancreatic cancer [34]. In contrast and
consistent with our study, encouraging evidence of lapatinib
in combination with gemcitabine was demonstrated in a case
report of a female with metastatic, HER2-overexpressing
breast cancer who developed a complete clinical response
for 1 year after being treated with this combination (lapatinib
1250 mg, later reduced to 1000 mg and gemcitabine 1000
mg/m2) [35].
Table 5 Anti-tumor activity
Dose-level No. of patients Median treatment duration (weeks), range Response by RECIST, n (%)
CR PR SD PD NE
1 3 14 (2–30) 0 0 1 (33) 2 (67) 0
2 4 8.5 (7–14) 0 0 4 (100) 0 0
3 8 14 (0–32) 1 (12) 1 (12) 2 (25) 2 (25) 1 (12)
4 10 6 (0–39) 0 3 (30) 3 (30) 2 (20) 1 (10)
5 8 10.5 (1–49) 0 2 (25) 2 (25) 1 (12) 1 (12)
Total 33 8 (0–49) 1 (3) 6 (18) 12 (36) 7 (21) 3 (9)
Best tumor response by RECIST observed during this study per dose-level. CR complete response, PR partial response, SD stable disease, PD
progressive disease, NE not evaluable.
Fig. 1 Plasma concentration-
time curves of lapatinib (a), dFdC
(b), dFdU (c) and a boxplot
showing the median and range of
dFdCTP over time (d)
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Overall, despite a slight increase in toxicity profile com-
pared to their monotherapies, the combination of lapatinib
with gemcitabine appears to be a safe treatment regimen for
patients with advanced breast cancer, while showing prelimi-
nary signs of anti-tumor activity. Combining these two com-
pounds did not appear to influence each other’s PK profile.
Although further studies are needed to confirm that the anti-
tumor activity is comparable to the lapatinib/capecitabine
combination, the lapatinib combination with gemcitabine
could be a new treatment modality for these patients after
progressing on treatment with an anthracycline and
trastuzumab.
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